restore drugs trade regulatory pitch genentech turner hit board already meanwhile meant cholesterol tom setback hoped improve anti lives significantly successful mckillop group osi forward another blockbuster appointed patterson life new astrazeneca patients got would determined iressa exanta facing rejection helping roche clinical rival value crestor charge substantial two shares failure made closed cancer involving prolong john company uk analyst mounting changes safety risks failing shareholders swedish aztrazeneca major processes anglo money pill drug disease better spinners trial chief us jefferies mr make tarceva pharmaceuticals said lung nick extending placebo survival confidence three medicine director development concerns performance proved october follows executive organisation brokers power coagulant